Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amazon.com, Inc. stock logo
AMZN
Amazon.com
$219.39
-1.8%
$203.30
$151.61
$242.52
$2.37T1.3442.09 million shs58.78 million shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$104.39
+1.0%
$106.68
$72.21
$139.13
$5.09B0.48671,398 shs609,879 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$48.64
+2.4%
$39.69
$30.04
$63.68
$4.10B1.751.87 million shs5.28 million shs
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$445.20
+0.9%
$453.85
$377.85
$519.88
$113.32B0.421.42 million shs1.11 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amazon.com, Inc. stock logo
AMZN
Amazon.com
0.00%+6.49%+9.50%+17.37%+15.55%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
0.00%+2.65%-1.49%-11.38%+28.40%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.00%+7.32%+31.77%+39.55%-12.07%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.00%+0.10%-0.39%-8.98%-5.85%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amazon.com, Inc. stock logo
AMZN
Amazon.com
4.6582 of 5 stars
3.53.00.03.02.73.31.9
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.6285 of 5 stars
4.51.00.04.51.44.20.6
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.9297 of 5 stars
4.31.00.00.02.02.50.6
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
4.6789 of 5 stars
3.35.00.03.33.32.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amazon.com, Inc. stock logo
AMZN
Amazon.com
2.98
Moderate Buy$245.8112.04% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3365.09% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$71.7547.51% Upside
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
2.54
Moderate Buy$511.6214.92% Upside

Current Analyst Ratings Breakdown

Latest VRTX, AMZN, AXSM, and CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/27/2025
Amazon.com, Inc. stock logo
AMZN
Amazon.com
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
6/27/2025
Amazon.com, Inc. stock logo
AMZN
Amazon.com
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$254.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
6/24/2025
Amazon.com, Inc. stock logo
AMZN
Amazon.com
Moffett Nathanson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$250.00 ➝ $253.00
6/23/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$550.00
6/20/2025
Amazon.com, Inc. stock logo
AMZN
Amazon.com
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$215.00 ➝ $250.00
6/20/2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$464.00 ➝ $460.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amazon.com, Inc. stock logo
AMZN
Amazon.com
$637.96B3.65$10.39 per share21.12$26.98 per share8.13
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.33N/AN/A$1.18 per share88.47
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M112.59N/AN/A$22.64 per share2.15
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$11.02B10.37N/AN/A$63.72 per share6.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amazon.com, Inc. stock logo
AMZN
Amazon.com
$59.25B$6.1435.7329.491.6810.14%24.14%10.90%7/30/2025 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A37.02N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
-$535.60M-$3.92N/A25.43N/A-8.91%-3.36%-2.42%7/30/2025 (Estimated)

Latest VRTX, AMZN, AXSM, and CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
5/5/2025Q1 2025
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
$4.29$4.06-$0.23$2.49$2.85 billion$2.77 billion
5/1/2025Q1 2025
Amazon.com, Inc. stock logo
AMZN
Amazon.com
$1.38$1.59+$0.21$1.59$154.96 billion$155.67 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amazon.com, Inc. stock logo
AMZN
Amazon.com
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amazon.com, Inc. stock logo
AMZN
Amazon.com
0.17
1.05
0.84
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.01
2.65
2.29

Institutional Ownership

CompanyInstitutional Ownership
Amazon.com, Inc. stock logo
AMZN
Amazon.com
72.20%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
90.96%

Insider Ownership

CompanyInsider Ownership
Amazon.com, Inc. stock logo
AMZN
Amazon.com
10.80%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.10%
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
0.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amazon.com, Inc. stock logo
AMZN
Amazon.com
1,556,00010.62 billion9.47 billionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.21 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
47386.36 million82.82 millionOptionable
Vertex Pharmaceuticals Incorporated stock logo
VRTX
Vertex Pharmaceuticals
6,100256.80 million256.28 millionOptionable

Recent News About These Companies

VRTX Vertex Pharmaceuticals Incorporated - Seeking Alpha
Equities Analysts Offer Predictions for VRTX Q3 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Amazon.com stock logo

Amazon.com NASDAQ:AMZN

$219.39 -3.91 (-1.75%)
As of 04:00 PM Eastern

Amazon.com, Inc. engages in the retail sale of consumer products, advertising, and subscriptions service through online and physical stores in North America and internationally. The company operates through three segments: North America, International, and Amazon Web Services (AWS). It also manufactures and sells electronic devices, including Kindle, Fire tablets, Fire TVs, Echo, Ring, Blink, and eero; and develops and produces media content. In addition, the company offers programs that enable sellers to sell their products in its stores; and programs that allow authors, independent publishers, musicians, filmmakers, Twitch streamers, skill and app developers, and others to publish and sell content. Further, it provides compute, storage, database, analytics, machine learning, and other services, as well as advertising services through programs, such as sponsored ads, display, and video advertising. Additionally, the company offers Amazon Prime, a membership program. The company's products offered through its stores include merchandise and content purchased for resale and products offered by third-party sellers. It serves consumers, sellers, developers, enterprises, content creators, advertisers, and employees. Amazon.com, Inc. was incorporated in 1994 and is headquartered in Seattle, Washington.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$104.39 +1.03 (+1.00%)
As of 04:00 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$48.64 +1.15 (+2.42%)
As of 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Vertex Pharmaceuticals stock logo

Vertex Pharmaceuticals NASDAQ:VRTX

$445.20 +3.90 (+0.88%)
As of 04:00 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.